PubRank

Jérôme Alexandre

Author PubWeight™ 29.78‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004 3.40
2 Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res 2005 3.12
3 Cost effectiveness of integrated medicine in patients with cancer receiving anticancer chemotherapy. J Oncol Pract 2012 1.50
4 Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo. Mol Cancer Ther 2012 1.13
5 Effect of integrated palliative care on the quality of end-of-life care: retrospective analysis of 521 cancer patients. BMJ Support Palliat Care 2012 1.09
6 An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity. Oncologist 2011 1.08
7 Arsenic trioxide exerts antitumor activity through regulatory T cell depletion mediated by oxidative stress in a murine model of colon cancer. J Immunol 2012 1.02
8 Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome? J Natl Cancer Inst 2007 0.96
9 Impact of FDG PET-CT imaging on the decision making in the biologic suspicion of ovarian carcinoma recurrence. Gynecol Oncol 2007 0.93
10 Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study. Target Oncol 2012 0.91
11 Treatment of oxaliplatin-induced peripheral neuropathy by intravenous mangafodipir. J Clin Invest 2013 0.90
12 Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathy. Anticancer Drugs 2005 0.84
13 Stimulation of angiogenesis resulting from cooperation between macrophages and MDA-MB-231 breast cancer cells: proposed molecular mechanism and effect of tetrathiomolybdate. BMC Cancer 2010 0.83
14 Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experience. Anticancer Drugs 2009 0.83
15 Bystander effect of vinorelbine alters antitumor immune response. Int J Cancer 2011 0.82
16 Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancer. Lung Cancer 2012 0.81
17 Combination of gemcitabine and oxaliplatin in urothelial cancer patients with severe renal or cardiac comorbidities. Anticancer Drugs 2005 0.81
18 Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib. Expert Opin Drug Metab Toxicol 2015 0.80
19 Hyper-alkalinization without hyper-hydration for the prevention of high-dose methotrexate acute nephrotoxicity in patients with osteosarcoma. Cancer Chemother Pharmacol 2010 0.79
20 CYP3A4/5 and pharmacogenetics in patients with sarcoma. Lancet Oncol 2007 0.78
21 Characterization and multiparameter analysis of visual adverse events in irofulven single-agent phase I and II trials. Clin Cancer Res 2004 0.78
22 [Use of antioxidant and other complementary medicine by patients treated by antitumor chemotherapy: a prospective study]. Bull Cancer 2011 0.78
23 Nutritional status is superior to the ECOG performance status in predicting the dose-intensity of the GEMOX chemotherapy regimen in patients with advanced cancer. Nutr Cancer 2013 0.78
24 Safety of bevacizumab 7.5 mg/kg infusion over 10 minutes in NSCLC patients. Invest New Drugs 2011 0.77
25 Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients. Cancer Chemother Pharmacol 2009 0.77
26 A new strategy to target regulatory T cells in solid tumors. Oncoimmunology 2013 0.77
27 An original administration of ifosfamide given once every other week: a clinical and pharmacological study. Anticancer Drugs 2008 0.76
28 A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors. Invest New Drugs 2006 0.76
29 A Real-Life Experience of Bevacizumab in Elderly Women With Advanced Ovarian Carcinoma. Int J Gynecol Cancer 2016 0.76
30 A potentially neuroprotective role for erythropoietin with paclitaxel treatment in ovarian cancer patients: a prospective phase II GINECO trial. Support Care Cancer 2013 0.75
31 Association between high antitumor activity of oxaliplatin and cyclophosphamide and constitutional GSTM1 homozygous deletion in an advanced ovarian cancer patient. Chemotherapy 2014 0.75
32 Primitive neuroectodermal tumor of the myometrium with cardio-vascular symptoms. Gynecol Oncol 2007 0.75
33 A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer. Breast Cancer Res Treat 2011 0.75
34 [Role of antioxidant complements and supplements in oncology in addition to an equilibrate regimen: a systematic review]. Bull Cancer 2009 0.75
35 [Fruits, vegetables . . . but not antioxidant]. Bull Cancer 2009 0.75
36 [Ovarian immature teratoma during pregnancy]. Presse Med 2010 0.75
37 Gynecologic Cancer InterGroup (GCIG) consensus review for squamous cell carcinoma of the ovary. Int J Gynecol Cancer 2014 0.75
38 Is thrombotic microangiopathy associated with antitumoral activity? Gynecol Oncol 2006 0.75